Payment overview · 2025
General Payments
$1,276.82
51 reported records · 17 companies
Healthcare provider profile · identity verified
Mohammed M Rahman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELMHURST, NY · NPI 1215971262
Verified facts
What the public records show
CMS Open Payments records show Mohammed M Rahman, M.D. received $1,276.82 in general payments during 2025 across 51 reported records.
Ardelyx, Inc. accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Shingrix, Voquezna, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 819 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 571 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $165.07 | 12.9% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $158.78 | 12.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.26 | 11.8% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $146.75 | 11.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.41 | 7.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $84.05 | 6.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $80.74 | 6.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.61 | 5.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.82 | 4.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $54.37 | 4.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.82 | 3.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.38 | 3.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.47 | 2.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.49 | 2.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.69 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,276.82 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $165.07 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $158.78 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $146.75 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $84.05 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $79.16 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.61 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.61 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.10 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.82 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $60.82 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $54.37 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.41 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 27 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 60 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
220 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
107 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
819 | 180 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
127 | 49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
571 | 106 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 50 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2533 | 662 |
| Losartan Potassium | Losartan Potassium | 1853 | 480 |
| Famotidine | Famotidine | 1825 | 481 |
| Omeprazole | Omeprazole | 1692 | 441 |
| Gabapentin | Gabapentin | 1445 | 386 |
| Amlodipine Besylate | Amlodipine Besylate | 1337 | 363 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1174 | 273 |
| Levothyroxine Sodium | Levothyroxine Sodium | 966 | 252 |
| Tamsulosin Hcl | Tamsulosin Hcl | 966 | 270 |
| Metoprolol Succinate | Metoprolol Succinate | 941 | 252 |
| Farxiga | Dapagliflozin Propanediol | 819 | 180 |
| Diclofenac Sodium | Diclofenac Sodium | 782 | 261 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 745 | 149 |
| Fenofibrate | Fenofibrate | 651 | 172 |
| Simvastatin | Simvastatin | 626 | 165 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 612 | 174 |
| Donepezil Hcl | Donepezil Hcl | 594 | 149 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 584 | 219 |
| Jardiance | Empagliflozin | 571 | 106 |
| Metformin Hcl | Metformin Hcl | 565 | 170 |
| Fluticasone Propionate | Fluticasone Propionate | 547 | 304 |
| Montelukast Sodium | Montelukast Sodium | 547 | 143 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 447 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 129 |
| Clopidogrel | Clopidogrel Bisulfate | 415 | 118 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 408 | 158 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 365 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 365 | 100 |
| Glipizide Er | Glipizide | 361 | 104 |
| Finasteride | Finasteride | 346 | 91 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 341 | 86 |
| Metformin Hcl Er | Metformin Hcl | 332 | 96 |
| Meclizine Hcl | Meclizine Hcl | 326 | 108 |
| Lisinopril | Lisinopril | 310 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 300 | 78 |
| Amitriptyline Hcl | Amitriptyline Hcl | 298 | 85 |
| Alendronate Sodium | Alendronate Sodium | 295 | 81 |
| Trulicity | Dulaglutide | 294 | 65 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 282 | 69 |
| Azithromycin | Azithromycin | 240 | 178 |
| Atenolol | Atenolol | 231 | 61 |
| Januvia | Sitagliptin Phosphate | 230 | 42 |
| Sertraline Hcl | Sertraline Hcl | 229 | 62 |
| Carvedilol | Carvedilol | 228 | 54 |
| Ammonium Lactate | Ammonium Lactate | 226 | 78 |
| Fenofibrate | Fenofibrate Nanocrystallized | 224 | 60 |
| Linzess | Linaclotide | 220 | 51 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 219 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 74 |
| Meloxicam | Meloxicam | 201 | 132 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 197 | 51 |
| Ketoconazole | Ketoconazole | 168 | 47 |
| Single Use Swab | Alcohol Antiseptic Pads | 168 | 79 |
| Folic Acid | Folic Acid | 163 | 46 |
| Clobetasol Propionate | Clobetasol Propionate | 151 | 45 |
| Ezetimibe | Ezetimibe | 149 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 146 | 74 |
| Repaglinide | Repaglinide | 143 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 32 |
| Furosemide | Furosemide | 137 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 135 | 37 |
| Pregabalin | Pregabalin | 133 | 24 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 130 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 127 | 49 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 126 | 52 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 126 | 42 |
| Eliquis | Apixaban | 123 | 30 |
| Halobetasol Propionate | Halobetasol Propionate | 121 | 72 |
| Prednisone | Prednisone | 118 | 87 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 116 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 33 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 113 | 40 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 26 |
| Brilinta | Ticagrelor | 107 | 24 |
| Myrbetriq | Mirabegron | 107 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 32 |
| Sucralfate | Sucralfate | 105 | 28 |
| Procto-Med Hc | Hydrocortisone | 104 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 102 | 30 |
| Ibuprofen | Ibuprofen | 100 | 79 |
| Nifedipine Er | Nifedipine | 98 | 24 |
| Entresto | Sacubitril/Valsartan | 96 | 22 |
| Clonidine Hcl | Clonidine Hcl | 94 | 22 |
| Hydrocortisone | Hydrocortisone | 93 | 63 |
| Ozempic | Semaglutide | 90 | 20 |
| Ranolazine Er | Ranolazine | 90 | 26 |
| Allopurinol | Allopurinol | 88 | 21 |
| Mirtazapine | Mirtazapine | 86 | 25 |
| Jentadueto | Linagliptin/Metformin Hcl | 85 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 84 | 40 |
| Nitroglycerin | Nitroglycerin | 82 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 26 |
| Clotrimazole | Clotrimazole | 79 | 57 |
| Lactulose | Lactulose | 79 | 25 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 76 | 25 |
| Novolog Flexpen | Insulin Aspart | 76 | 26 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 74 | 13 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 73 | 31 |
| Latanoprost | Latanoprost | 71 | 21 |
| Xarelto | Rivaroxaban | 71 | 18 |
| Alcohol Swab | Alcohol Antiseptic Pads | 70 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 22 |
| Memantine Hcl | Memantine Hcl | 68 | 18 |
| Naproxen | Naproxen | 68 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 49 |
| Loperamide | Loperamide Hcl | 67 | 46 |
| Tradjenta | Linagliptin | 66 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 65 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 61 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 39 |
| Risperidone | Risperidone | 59 | 16 |
| Methimazole | Methimazole | 57 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 16 |
| Vascepa | Icosapent Ethyl | 54 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 19 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 53 | 22 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 52 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 34 |
| Labetalol Hcl | Labetalol Hcl | 47 | 14 |
| Propranolol Hcl | Propranolol Hcl | 47 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 47 | 14 |
| Glipizide Xl | Glipizide | 46 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 42 |
| Proctozone-Hc | Hydrocortisone | 45 | 19 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 23 |
| Trazodone Hcl | Trazodone Hcl | 44 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 43 | 11 |
| Methotrexate | Methotrexate Sodium | 43 | suppressed |
| Glimepiride | Glimepiride | 41 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | 12 |
| Timolol Maleate | Timolol Maleate | 41 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 41 | 21 |
| Spironolactone | Spironolactone | 40 | 12 |
| Valsartan | Valsartan | 39 | 14 |
| Gemfibrozil | Gemfibrozil | 38 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Ramipril | Ramipril | 38 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 37 | suppressed |
| Levemir Flexpen | Insulin Detemir | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 13 |
| Nystatin | Nystatin | 36 | 21 |
| Levetiracetam | Levetiracetam | 35 | 11 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | 21 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 27 |
| Azelastine Hcl | Azelastine Hcl | 31 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | 12 |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 29 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | 15 |
| Amoxicillin | Amoxicillin | 29 | 27 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 29 | 24 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 26 |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Permethrin | Permethrin | 26 | 13 |
| Topiramate | Topiramate | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Voquezna | Vonoprazan Fumarate | 19 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | 12 |
| Trulance | Plecanatide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Segluromet | Ertugliflozin/Metformin | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,276.82 · 51 records | Ardelyx, Inc. | AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, IBSRELA, INGREZZA, NEXLETOL, OTEZLA, REPATHA, SHINGRIX, Symbravo, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error